Success Metrics

Clinical Success Rate
85.7%

Based on 12 completed trials

Completion Rate
86%(12/14)
Active Trials
0(0%)
Results Posted
25%(3 trials)
Terminated
2(14%)

Phase Distribution

Ph phase_1
5
36%
Ph phase_2
9
64%

Phase Distribution

5

Early Stage

9

Mid Stage

0

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
5(35.7%)
Phase 2Efficacy & side effects
9(64.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

85.7%

12 of 14 finished

Non-Completion Rate

14.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(12)
Terminated(2)

Detailed Status

Completed12
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
85.7%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (35.7%)
Phase 29 (64.3%)

Trials by Status

terminated214%
completed1286%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_2

SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer

NCT00095992
terminatedphase_1

A Study of Ispinesib in Metastatic Breast Cancer

NCT00607841
completedphase_2

Study Of Ispinesib In Subjects With Breast Cancer

NCT00089973
completedphase_2

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00095628
completedphase_2

SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer

NCT00103311
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT00095992Phase 2

SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer

Completed
NCT00607841Phase 1

A Study of Ispinesib in Metastatic Breast Cancer

Terminated
NCT00089973Phase 2

Study Of Ispinesib In Subjects With Breast Cancer

Completed
NCT00095628Phase 2

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Completed
NCT00103311Phase 2

SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer

Completed
NCT00354250Phase 2

Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer

Completed
NCT00095953Phase 2

SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma

Completed
NCT00096499Phase 2

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

Completed
NCT00363272Phase 1

Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma

Completed
NCT00101244Phase 1

SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma

Terminated
NCT00098826Phase 1

SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes

Completed
NCT00097409Phase 2

Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer

Completed
NCT00085813Phase 2

Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

Completed
NCT00119171Phase 1

Ispinesib In Combination With Capecitabine In Patients With Solid Tumors

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14